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The objective of this study was to characterise the mechanism mediating the prostate cancer progression induced by the
microenvironment of seminal vesicle (SV). The invasive potential of PC3 cells significantly increased after treatment with extract from
SV of NOD/SCID mouse. Among several growth factors and cytokines that were present in the SV extract, transforming growth
factor-b1 (TGF-b1) significantly enhanced the invasive potential of PC3 cells; however, the additional treatment with neutralising
antibody against TGF-b1 suppressed the enhanced invasive potential induced by the SV extract. Changes in the invasive potential in
PC3 cells after treatment with the SV extract and/or TGF-b1 were in proportion to those in the production of urokinase-type
plasminogen activator (uPA) by PC3 cells. Tumour growth as well as the incidence of lymph node metastasis in NOD/SCID mice
after the injection of PC3 cells into the SV were significantly greater than those after the injection into the prostate. These findings
suggest that the microenvironment of SV enhances the progression of prostate cancer through a stimulated invasive potential, and
that enhanced uPA production in prostate cancer cells induced by TGF-b1 could therefore be one of the most important
mechanisms involved in the progression of prostate cancer after SV invasion.
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Invasion of prostate cancer cells into the seminal vesicle (SV) is an
adverse prognostic factor in patients undergoing radical prosta-
tectomy. Contemporary series analysing outcomes of radical
prostatectomy reported that biochemical recurrence occurred in
more than 50% of patients with SV invasion (Sofer et al, 2003;
Bloom et al, 2004). However, SV invasion has been shown to lack a
systematic relationship with other potential pathological factors
indicating a poor prognosis, and there has not been any
independent prognostic predictor in patients with SV invasion
(Sofer et al, 2003; Masterson et al, 2005). These findings suggest
that adverse features of prostate cancer with SV invasion may be
due to an acquired aggressive phenotype rather than ‘volume
effect’ as a result of disease progression.
The outcome of cancer progression depends on multiple
interactions of cancer cells with various host factors; that is, the
interaction of tumour cells with the organ environment modulates
the tumorigenic properties by regulating their phenotypes, such as
cell proliferation, motility and invasion (Fidler, 1990). A number of
studies have demonstrated significant effects of organ microenvi-
ronment on the malignant potentials in several types of cancer
cells, including prostate cancer, using in vivo experimental models
(Gohji et al, 1997; Sato et al, 1997; Alencar et al, 2005). For
example, Gohji et al reported that human renal cancer cells
implanted in the subcutis of nude mice produced local nonmeta-
static tumours, whereas the same cells orthotopically implanted in
the kidney resulted in the formation of local tumours and
metastases to the lungs. Furthermore, they clarified the important
role of proteolytic enzymes whose production is influenced by the
organ microenvironment, in the progression of implanted renal
cell carcinoma cells (Gohji et al, 1997).
To date, the molecular mechanism mediating disease progres-
sion following SV invasion has remained largely unknown, and
there is no study analysing whether the malignant phenotype of
prostate cancer cells is affected by the microenvironment of SV.
We, therefore, developed an implantation model of human
prostate cancer cells to the SV of immunodeficient mice, resulting
in systemic disease progression in vivo, and investigated the
mechanism underlying the modulation of malignant potential of
human prostate cancer cells induced by the microenvironment
of SV.
MATERIALS AND METHODS
Reagents
Recombinant human transforming growth factor-b1 (TGF-b1),
basic fibroblast growth factor, hepatocyte growth factor, platelet-
derived growth factor, granulocyte colony-stimulating factor, anti-
human TGF-b1 antibody, and anti-human epidermal growth factor
(EGF) antibody were from R&D Systems (Minneapolis, MN, USA).
Recombinant human EGF, granulocyte monocyte colony-stimulat-
ing factor, tumour necrosis factor-a, interkeukin-1b, interleukin-6,
fibronectin, and anti-rat b-tubulin antibody were from Chemicon
International (Temecula, CA, USA). Anti-human urokinase-type
plasminogen activator (uPA) antibody and quantitative sandwich
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senzyme immunoassay kit for human uPA were from American
Diagnostica (Greenwich, CT, USA). Horseradish peroxidase-
conjugated anti-mouse IgG antibody was from Amersham Life
Science (Arlington Heights, IL, USA). Biotinylated goat anti-mouse
IgG was from Vector Laboratories (Burlingame, CA, USA).
Tumour cell line
PC3, derived from human prostate cancer, was purchased from the
American Type Culture Collection (Rockville, MD, USA). Cells
were maintained in DMEM (Life Technologies Inc., Gaithersburg,
MD, USA) supplemented with 5% heat-inactivated fetal calf serum.
Preparation of extracts from the SV and prostate
After 12-week-old nonobese diabetic/severe combined immuno-
deficient (NOD/SCID) mice (CLEA Japan Inc., Tokyo, Japan) were
killed, SV and prostate were harvested, washed with PBS, and
disrupted using a sonicator (Ultrasonic Systems Inc., Haverhill,
MA, USA). Following centrifugation of the respective extracts of
SV and prostate, each supernatant was stored at  801C until used.
In vitro cell growth assay
The effects of extract from the SV or prostate on the in vitro
growth of PC3 cells were assessed using MTT (Sigma Chemical Co.,
St Louis, MO, USA) as described previously (Yamanaka et al,
2005). Briefly, 1 10
4 cells were seeded in each well of 96-well
microtitre plates and allowed to attach overnight. Cells were then
treated with various concentrations of either SV or prostate extract
diluted with serum-free DMEM/F12. After 48h of incubation, 20ml
of 5mgml
 1 MTT in PBS was added to each well, followed by
incubation for 4h at 371C. The formazan crystals were dissolved in
DMSO. The optical density was determined with a microculture
plate reader (Becton Dickinson Labware, Lincoln Park, NJ, USA) at
540nm. Absorbance values were normalised to the values obtained
for vehicle-treated cells. Each assay was performed in triplicate.
In vitro tumour cell invasion assay
Tumour cell invasion was measured using cell invasion assay kit
(Chemicon) as described previously (Miyake et al, 1999a). Briefly,
we used polycarbonate filters with a pore size of 8mm coated with
basement membrane Matrigel. The coated filters were placed in
Boyden chambers, in the upper compartment of which 1 10
5 cells
were suspended in serum-free DMEM/F-12 followed by treatment
with extract from the SV or prostate and/or growth factor or
cytokine and in the lower compartment of which 25mgml
 1
fibronectin diluted with serum-free DMEM/F-12 were added as a
chemoattractant. After 48h incubation at 371C, cells on the top
side of the filter were removed, and cells that had migrated and
invaded the Matrigel through the filter and attached to the bottom
of the membrane were stained with crystal violet stain solution.
The crystal violet stain solution was eluted with 10% acetic acid
extraction buffer and transferred to wells of a 96-well microtitre
plate, and the absorbance was read with a microculture plate
reader (Becton Dickinson Labware) at 540nm. Absorbance values
were normalised by the values obtained for the vehicle-treated
cells. Similarly, cell motility was also assessed using the Boyden
chambers without matrigel. Each assay was performed in triplicate.
Measurement of uPA levels in conditioned media
The concentrations of uPA in conditioned media were determined
using a quantitative sandwich enzyme immunoassay kit for human
uPA as described previously (Miyake et al, 1999b). Briefly, PC3
cells were seeded in each well of 96-well microtitre plates and
allowed to attach overnight. Cells were then treated with extract
from the SV, TGF-b1, and/or anti-TGF-b1 antibody diluted with
serum-free DMEM/F-12. After 48h of incubation, serum-free
DMEM/F-12 was collected. For each analysis, 100ml of conditioned
media were added to microtitre plates coated with a purified
polyclonal antibody against human uPA. Bound uPA was detected
by an additional biotinylated anti-uPA antibody. After the addition
of streptavidin-conjugated horseradish peroxidase, peroxidase-
mediated conversion of 3,30,5,50-tetramethylbenzene was measured
with a microculture plate reader (Becton Dickinson Labware) at
450nm. Each assay was performed in triplicate.
Western blot analysis
Western blot analysis was used to evaluate the expression level of
uPA protein in PC3 cells after treatment with extract from the SV
and/or anti-TGF-b1 antibody as described previously (Miyake et al,
1999a). Briefly, samples containing equal amounts of protein (15mg)
from lysates of the cultured PC3 cells were electrophoresed on an
SDS-polyacrylamide gel and transferred to a nitrocellulose filter. The
filters were blocked in PBS containing 5% nonfat milk powder at
41C overnight and then incubated for 1h with a 1:400-diluted anti-
human uPA mouse antibody or 1:10000-diluted anti-rat b-tubulin
mouse antibody. The filters were then incubated for 30min with
horseradish peroxidase-conjugated anti-mouse IgG antibody, and
specific proteins were detected using an enhanced chemilumines-
cence western blotting analysis system (Amersham Life Science).
Assessment of in vivo tumour growth
Male NOD/SCID mice, 10- to 12-week-old, (CLEA Japan Inc.) were
housed in a controlled environment at 221C on a 12-h light and
12-h dark cycle. Animals were maintained in accordance with
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals. Each experimental group consisted of 10
mice. PC3 cells were trypsinised, washed twice with PBS, and
5 10
5 cells suspended in 20ml of PBS were directly injected into
the SV or the dorsal love of the prostate under the prostatic
capsule. Eight weeks after the injection of tumour cells, the mice
were killed and the presence of metastasis was macroscopically
examined in all abdominal organs, and the weight of each tumour
formed in the SV or prostate was measured.
Statistical analysis
Differences between the two groups were compared using the
w
2-test, unpaired t-test or Mann–Whitney U-test. All statistical
calculations were performed using Statview 5.0 software (Abacus
Concepts Inc., Berkley, CA, USA), and P-values o0.05 were
considered significant.
RESULTS
Changes in the malignant phenotype of PC3 cells induced
by extract from the SV or prostate
We initially evaluated the effects of SV or prostate extract on the
malignant potential of PC3 cells. As shown in Figure 1, neither the
SV or prostate extract had any impact on cell growth or motility of
PC3 cells. However, despite the lack of significant effect of prostate
extract on the invasive potential of PC3 cells, treatment of PC3
cells with SV extract increased the invasive potential in a dose-
dependent manner.
Influence of growth factors and cytokines on the invasive
potential of PC3 cells
To identify candidate factor responsible for the enhanced invasive
potential of PC3 cells induced by SV extract, the abilities of 10
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skinds of growth factors or cytokines to increase the invasive
potential of PC3 cells were evaluated. Of the 10 factors tested,
TGF-b1 and EGF significantly stimulated the invasive potential of
PC3 cells (Figure 2A). Furthermore, treatment with both TGF-b1
and EGF increased in the invasive potential of PC3 cells in dose-
dependent manners (Figure 2B). We then examined whether
antibody against TGF-b1 or EGF suppresses the enhanced invasive
potential of PC3 cells induced by the SV extract. As shown in
Figure 2C, anti-TGF-b1 antibody inhibited the invasive potential of
PC3 cells in a dose-dependent manner, while the invasive ability of
PC3 cells stimulated by SV extract was not affected by anti-EGF
antibody. These results suggest that TGF-b1 in seminal plasma may
be involved in the enhanced invasive potential of PC3 cells induced
by the SV extract.
Regulation of uPA production in PC3 cells by TGF-b1
To investigate the mechanism mediating the stimulation of
invasive potential of PC3 cells by treatment with TGF-b1,w e
analysed the role of uPA, one of the most important proteolytic
enzymes involved in tumour cell invasion (Festuccia et al, 1998), in
this process. Treatment of PC3 cells by TGF-b1 resulted in a dose-
dependent increase in uPA production released in the culture
medium (Figure 3A). Furthermore, the SV extract also induced
increased uPA production by PC3 cells in a dose-dependent
manner; however, this stimulated production of uPA by treatment
with the SV extract was significantly inhibited by additional
treatment with anti-TGF-b1 antibody (Figure 3B). Western blot
analysis was used to measure changes in the expression levels of
uPA protein in PC3 cells following treatment with SV extract and/
or anti-TGF-b1 antibody. As shown in Figure 3C, uPA protein
expression in PC3 cells was enhanced by treatment with SV extract
in a dose-dependent manner, whereas treatment with anti-TGF-b1
antibody resulted in the suppression of enhanced uPA protein
expression by the SV extract in PC3 cells.
Disease progression following the injection of PC3 cells
into the SV in NOD/SCID mice
To compare the effects of organ microenvironment between SV
and prostate on the disease progression of PC3 tumours in vivo,w e
injected PC3 cells into either the SV or prostate in NOD/SCID
mice. The mice were killed 8 weeks after the tumour cell injection,
during which we found that the weight of tumours in mice
receiving SV injection was significantly greater than that in mice
receiving prostate injection. Furthermore, the incidence of retro-
peritoneal lymph node metastases in mice receiving SV injection
was significantly higher than that in mice receiving prostate
injection (Table 1). In addition, haemorrhagic ascites was observed
only in the mice following SV injection.
DISCUSSION
Although SV invasion has been regarded as one of the most potent
factors related to an adverse prognosis in patients undergoing
radical prostatectomy (Sofer et al, 2003; Bloom et al, 2004), the
molecular mechanism mediating the progression of prostate
cancer following the invasion of cancer cells into the SV remains
largely unknown. To date, a number of studies have demonstrated
a significant impact of organ microenvironment on disease
progression of various types of human malignant tumours (Gohji
et al, 1997; Sato et al, 1997; Alencar et al, 2005); however, there
have not been any studies investigating the significance of the SV
microenvironment as a factor influencing the progression of
prostate cancer. In this study, therefore, we focused on the role of
microenvironment of the SV, and evaluated its effects on changes
in malignant phenotypes of human prostate cancer PC3 cells both
in vitro and in vivo.
It was initially examined whether the SV or prostate extract
influences the malignant potential of PC3 cells, and demonstrated
that despite the lack of a significant effect of prostate extract, the
invasive potential of PC3 cells was markedly enhanced by SV extract.
To identify the factors in SV extract mediating the stimulation of
invasive potential, we examined the effects of 10 different growth
factors or cytokines that have been shown to be abundantly present
in seminal plasma (Matalliotakis et al, 1998; Robertson, 2005) and/or
associated with the invasion of prostate cancer cells (Barton et al,
2001; Bindukumar et al, 2005). Of the 10 factors examined in this
study, TGF-b1 and EGF were found to significantly stimulate the
invasive potential of PC3 cells; however, anti-TGF-b1 antibody, but
not anti-EGF antibody, suppressed the enhanced invasive potential
of PC3 cells induced by SV extract. These findings suggest that TGF-
b1 may, at least in part, be involved in the increased invasive
potential of PC3 cells induced by SV extract.
It is of interest to clarify the mechanism by which TGF-b1
induces the increased invasive potential of PC3 cells. Several
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Figure 1 Effects of treatment with extract of either prostate or seminal
vesicle (SV) on malignant phenotypes, including cell growth, motility and
invasion, in human prostate cancer PC3 cells. (A) PC3 cells were treated
with various concentrations of the prostate or SV extract diluted with
serum-free DMEM/F12. After 48h of incubation, the number of viable cells
was determined by the MTT assay. Columns, mean of three independent
experiments; bars, s.d. (B) PC3 cells seeded at 1 10
5 per well in Boyden
chambers were treated with various concentrations of the prostate or SV
extract diluted with serum-free DMEM/F12. Chambers were incubated for
48h in serum-free DMEM/F12, and then cells that had migrated to the
lower surface of filters were stained with crystal violet stain solution.
After the elution of crystal violet, the absorbance value in each well was
measured with a microculture plate reader. Columns, mean of three
independent experiments; bars, s.d. (C) PC3 cells seeded at 1 10
5 per
well in Boyden chambers were treated with various concentrations of the
prostate or SV extract diluted with serum-free DMEM/F12. Chambers
were incubated for 48h, and then cells that had migrated to the lower
surface of filters through reconstituted basement membrane Matrigel were
stained with crystal violet stain solution. After the elution of crystal violet,
the absorbance value in each well was measured with a microculture plate
reader. Columns, mean of three independent experiments; bars, s.d.
*, differs from control (Po0.01).
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sprevious studies have shown that TGF-b1 enhances the secretion of
proteolytic enzymes in prostate cancer cells, which helps degrade
the connective tissue extracellular matrix and basement membrane
components (Festuccia et al, 2000; Unlu and Leake, 2003). Among
these enzymes involved in tumour cell invasion, uPA is one of the
most predominant factors involved in the disease progression of
malignant tumours (Choong and Nadesapillai, 2003). In prostate
cancer as well, accumulating evidence strongly suggests the
important role of uPA in the disease progression of prostate
cancer (Pulukuri et al, 2005; Usher et al, 2005; Shariat et al, 2007).
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Figure 2 Effects of treatment with growth factors and cytokines on invasive potential in human prostate cancer PC3 cells. (A) PC3 cells seeded at 1 10
5
per well in Boyden chambers were treated with 1ngml
 1 transforming growth factor-b1 (TGF-b1), 1ngml
 1 epidermal growth factor (EGF), 10ngml
 1
basic fibroblast growth factor (bFGF), 10ngml
 1 hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), 10ngml
 1 granulocyte colony-
stimulating factor (G-CSF), 10ngml
 1 granulocyte monocyte colony-stimulating factor (GM-CSF), 100Uml
 1 tumour necrosis factor-a (TNF-a),
100Uml
 1 interkeukin-1b (IL-1b)o r1 0n gm l
 1 interleukin-6 (IL-6) diluted with serum-free DMEM/F12. Chambers were incubated for 48h, and then cells
that had migrated to the lower surface of filters through reconstituted basement membrane Matrigel were stained with crystal violet stain solution. After the
elution of crystal violet, the absorbance value in each well was measured with a microculture plate reader. No Tx, untreated cells. Columns, mean of three
independent experiments; bars, s.d. *, differs from control (Po0.01). (B) PC3 cells seeded at 1 10
5 per well in Boyden chambers were treated with
various doses of TGF-b1 or EGF diluted with serum-free DMEM/F12. Chambers were incubated for 48h, and then cells that had migrated to the lower
surface of filters through reconstituted basement membrane Matrigel were stained with crystal violet stain solution. After the elution of crystal violet, the
absorbance value in each well was measured with a microculture plate reader. Columns, mean of three independent experiments; bars, s.d. ** and *, differs
from control (Po0.01 and Po0.05, respectively). (C) PC3 cells seeded at 1 10
5 per well in Boyden chambers were treated with 10mgml
 1 seminal
vesicle extract and various doses of anti-TGF-b1 or anti-EGF antibody diluted with serum-free DMEM/F12. Chambers were incubated for 48h, and then cells
that had migrated to the lower surface of filters through reconstituted basement membrane Matrigel were stained with crystal violet stain solution. After the
elution of crystal violet, the absorbance value in each well was measured with a microculture plate reader. Columns, mean of three independent
experiments; bars, s.d. *, differs from control (Po0.01).
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sFor example, Pulukuri et al (2005) reported that RNA interference-
directed knockdown of uPA and its receptor in PC3 cells
significantly reduced tumour cell viability and invasion, and
ultimately resulted in the induction of apoptotic cell death.
Considering these findings, in this study, we analysed the TGF-
b1-induced stimulation of invasive potential in PC3 cells focusing
on the role of uPA. Interestingly, treatment of PC3 cell with TGF-b1
enhanced their secretion of uPA in a dose-dependent manner. In
addition, inhibition of TGF-b1 activity in the SV extract resulted
in the suppression of uPA production in PC3 cells, which was
proportional to their invasive potential. Collectively, these results
indicated the potential role of uPA in TGF-b1-mediated enhanced
invasive potential of PC3 cells.
To compare the different effects of organ microenvironment
between the SV and prostate on disease progression in vivo,w e
directly injected PC3 cells into the SV or prostate in NOD/SCID
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Figure 3 Regulation of urokinase-type plasminogen activator production in human prostate cancer PC3 cells by transforming growth factor-b1 (TGF-b1).
(A) PC3 cells were treated with various concentrations of TGF-b1 diluted with serum-free DMEM/F12. After 48h of incubation, serum-free DMEM/F12 was
collected, and the concentration of uPA in each sample was determined with a quantitative sandwich enzyme immunoassay kit for human uPA. Columns,
mean of three independent experiments; bars, s.d. *, differs from control (Po0.01). (B) PC3 cells were treated with various concentrations of seminal
vesicle (SV) extract and anti-TGF-b1 antibody diluted with serum-free DMEM/F12. After 48h of incubation, serum-free DMEM/F12 was collected, and the
concentration of uPA in each sample was determined with a quantitative sandwich enzyme immunoassay kit for human uPA. Columns, mean of three
independent experiments; bars, s.d. ** and *, differs from control (Po0.01 and Po0.05, respectively). (C) PC-3 cells were treated with various
concentrations of SV extract and/or anti-TGF-b1 antibody diluted with serum-free DMEM/F12. After 48h of incubation, protein was extracted from culture
cells, and uPA and b-tubulin protein levels were analysed by western blotting.
Table 1 Comparison of disease progression in vivo following the injection of PC3 cells into the prostate or SV
Prostate injection SV injection P-value
Incidence of lymph node metastasis (%)
a 2/10 (20) 7/10 (70) o0.05
Incidence of haemorrhagic ascites (%)
b 0/10 (0) 4/10 (40) o0.05
Weight of the primary tumor (mg)
c 22.8±8.7 40.7±10.6 o0.01
SV¼seminal vesicle.
aNo. of mice with lymph node metastases/no. of injected mice.
bNo. of mice with haemorrhagic ascites/no. of injected mice.
cMean±s.d.
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smice. A number of studies have demonstrated that cancer cells,
including prostate cancer, can achieve favourable environments
for disease progression in anatomically relevant (i.e., orthotopic)
organs (Gohji et al, 1997; Sato et al, 1997; Alencar et al, 2005). In
this study as well, lymph node metastases was observed in some
mice following injection of PC3 cells into the prostate as described
previously (Saffran et al, 2001); however, disease progression in
mice following the SV injection of PC3 cells was more prominent
than that in mice following intraprostatic injection. Furthermore,
we performed in vivo experiments injecting androgen-dependent
human prostate cancer LNCaP cells into the SV or the prostate of
NOD/SCID mice, and demonstrated that tumour growth as well as
the incidence of lymph node metastasis after the injection of
LNCaP cells into the SV were significantly greater than those after
the injection into the prostate (data not shown). To our knowledge,
this is the first study clearly showing that SV rather than the
orthotopic organ (i.e., prostate) provides a stimulating environ-
ment for the progression of prostate cancer cells.
Here, we would like to emphasise several limitations of this
study. First, the phenomenon of uPA induction by TGF-b1 may not
be entirely responsible for the enhanced invasive potential of PC3
cells by treatment with SV extract; that is, other molecules present
in the SV may be involved in promoting the invasive potential. In
addition, different mechanisms associated with the microenviron-
ment of the SV, such as the regulated production of proteolytic
enzymes by organ-specific fibroblasts (Gohji et al, 1997), may have
a significant impact on the disease progression following the
injection of PC3 cells into the SV. In fact, despite the lack of a
stimulatory effect of SV extract on the proliferation of PC3 cells,
injection of PC3 cells into the SV resulted in the enhanced
growth of PC3 tumours, suggesting the involvement of a
mechanism other than the SV extract-induced enhanced invasive
potential of PC3 cells in the disease progression of PC3 tumours
in vivo. It is also a limitation that the findings presented in this
study may not be uniformly true for a wide variety of cancer cells,
considering a divergent function of TGF-b1 in modulating the
malignant phenotype of cancer cells (Desruisseau et al, 1996;
Tuxhorn et al, 2002). Finally, we could not show in vivo data
supporting the hypothesis of this study; that is, there were no
characteristic findings on histological examinations of both
tumours developed after the injection of PC3 cells into the SV
and the prostate, such as those suggesting different metastatic
potentials, and both tumours were shown to exhibit strong uPA
expression by immunohistochemical staining (data not shown),
which may be due to the originally high expression level of uPA
in PC3 cells, resulting in the lack of evident difference in uPA
expression between tumours in the SV and the prostate.
Accordingly, to enhance the reliability of our findings, the
outcomes of this study should be confirmed using different kinds
of human prostate cancer model systems.
In conclusion, the findings presented in this study suggest that
the microenvironment of SV enhances the progression of prostate
cancer through a stimulated invasive potential, and that enhanced
uPA production in prostate cancer cells induced by TGF-b1, which
is abundantly present in seminal plasma, could therefore be one of
the most important mechanisms involved in the progression of
prostate cancer following SV invasion. To address the functional
impact of TGF-b1-induced uPA production on the progression of
prostate cancer in the microenvironment of SV, it would be
absolutely necessary to perform further experiments characterising
changes in malignant phenotype of PC3 cells both in vitro and
in vivo before and after the inactivation of TGF-b1 and/or uPA.
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